Latest filings (excl ownership)
10-K
2023 FY
Annual report
1 Apr 24
8-K
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
12 Mar 24
8-K
Departure of Directors or Certain Officers
12 Dec 23
8-K
Departure of Directors or Certain Officers
16 Nov 23
8-K
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
8 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Entry into a Material Definitive Agreement
27 Oct 23
DEFA14A
Additional proxy soliciting materials
22 Sep 23
DEF 14A
Definitive proxy
22 Sep 23
8-K
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
9 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Departure of Directors or Certain Officers
1 Aug 23
8-K
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results
12 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
8-K
Departure of Directors or Certain Officers
24 Apr 23
8-K
Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results
27 Mar 23
10-K
2022 FY
Annual report
27 Mar 23
8-K
Departure of Directors or Certain Officers
15 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results
14 Nov 22
8-K
Entry into a Material Definitive Agreement
4 Nov 22
8-K
Departure of Directors or Certain Officers
4 Oct 22
DEFA14A
Additional proxy soliciting materials
20 Sep 22
DEF 14A
Definitive proxy
20 Sep 22
PRE 14A
Preliminary proxy
9 Sep 22
8-K
Entry into a Material Definitive Agreement
7 Sep 22
8-K
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results
15 Aug 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
RW
Registration withdrawal request
16 Jun 22
10-Q
2022 Q1
Quarterly report
16 May 22
8-K
Interpace Biosciences Announces First Quarter 2022 Financial and Business Results
16 May 22
8-K
Entry into a Material Definitive Agreement
10 May 22
10-K/A
2021 FY
Annual report (amended)
29 Apr 22
8-K
Changes in Registrant's Certifying Accountant
14 Apr 22
8-K
Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results
31 Mar 22
10-K
2021 FY
Annual report
31 Mar 22
8-K
Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests
31 Jan 22
8-K
Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director
27 Jan 22
EFFECT
Notice of effectiveness
13 Jan 22
Latest ownership filings
SC 13G/A
Singer Douglas Mark
12 Feb 24
4
Christopher McCarthy
6 Feb 24
4
Christopher McCarthy
1 Aug 23
3
Christopher McCarthy
3 May 23
SC 13G/A
Singer Douglas Mark
10 Feb 23
SC 13G
Singer Douglas Mark
10 Feb 22
4
VIJAY AGGARWAL
2 Feb 22
3
VIJAY AGGARWAL
2 Feb 22
SC 13D/A
Kamin Peter
1 Feb 22
SC 13D/A
Kamin Peter
13 Jan 22
SC 13D/A
Kamin Peter
6 Dec 21
SC 13D/A
1315 Capital II, L.P.
12 Nov 21
SC 13D/A
Ampersand 2018 Limited Partnership
12 Nov 21
4
Thomas W. Burnell
25 May 21
SC 13D/A
1315 Capital II, L.P.
20 May 21
SC 13D/A
Ampersand 2018 Limited Partnership
18 May 21
4
Thomas John Freeburg
12 Mar 21
4
Peter Kamin
1 Mar 21
3
Peter Kamin
1 Mar 21
SC 13D
Kamin Peter
1 Mar 21
SC 13G/A
Stonepine Capital Management, LLC
12 Feb 21
4
Robert J. Gorman
2 Feb 21
SC 13D/A
1315 Capital II, L.P.
21 Jan 21
SC 13D/A
Ampersand 2018 Limited Partnership
19 Jan 21
4
JACK E STOVER
2 Dec 20
4
Thomas W. Burnell
2 Dec 20
3
Thomas W. Burnell
2 Dec 20
SC 13G
Stonepine Capital Management, LLC
11 Sep 20
SC 13D/A
Binsalamah Ziyad
20 Aug 20
4
James Early
31 Jul 20
SC 13D
Binsalamah Ziyad
24 Jul 20
4
Robert J. Gorman
13 Jul 20
4
STEPHEN J SULLIVAN
10 Jul 20
4
Fortunato R. Rocca
10 Jul 20
4
JOSEPH D KEEGAN
10 Jul 20
SC 13D/A
1315 Capital II, L.P.
30 Apr 20
SC 13D/A
Ampersand 2018 Limited Partnership
23 Apr 20
SC 13G
Stonepine Capital Management, LLC
17 Apr 20
4
JACK E STOVER
6 Apr 20
4/A
Gregory Richard
10 Feb 20